For US Healthcare Professionals only.
VABOMERE is supplied as a white to light yellow sterile powder for constitution in single-dose, clear glass vials that contain 2 grams of VABOMERE. Each vial contains 1 gram of meropenem (equivalent to 1.14 grams of meropenem trihydrate), 1 gram of vaborbactam, and 0.575 gram of sodium carbonate.
ONE BOX is ONE DAY of treatment.*
VABOMERE 4 g (2 g meropenem and 2 g vaborbactam)
NDC NO.
70842‑0120‑06
Each vial contains VABOMERE 2 g (1 g meropenem and 1 g vaborbactam) for injection and is supplied in a box of 6 vials.
Typical full course of daily treatment for patients with eGFR ≥50 mL/min/1.73 m2. Additional dosing information for patients with renal impairment can be found in the Dosing section of this website.
VABOMERE is a wholesaler-stocked product. Please use standard ordering procedure through your wholesaler. If product is not available at your wholesaler, your wholesaler can easily coordinate a drop shipment via Next Day Saver from a Melinta primary distribution provider by calling your wholesaler‘s customer service number listed below.
References: 1. VABOMERE [package insert]: Melinta Therapeutics, LLC.
VABOMERE® (meropenem and vaborbactam) is indicated for the treatment of patients 18 years of age and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae species complex.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of VABOMERE and other antibacterial drugs, VABOMERE should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
VABOMERE is contraindicated in patients with known hypersensitivity to any components of VABOMERE (meropenem and vaborbactam), or to other drugs in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactam antibacterial drugs.
The most frequently reported adverse reactions occurring in ≥3% of patients treated with VABOMERE were headache, phlebitis/infusion site reactions, and diarrhea.
Please see full Prescribing Information.